Compared to other classification system, EAp53 scores might currently be the most powerful prognostication tool for categorizing patients harboring TP53 mutations in advanced NSCLC regardless of targeted therapies and chemotherapies. Here, TP53 is linked to non-small cell lung carcinoma.